Search PubMed⌕ Search

Biomedical subjects

M C Beinfeld

Publications and source records attributed to M C Beinfeld.

At least 73 records · Page 4Linked to original sources

Blood pressure increases after injection of neuropeptide Y into posterior hypothalamic nucleus.

Unilateral microinjection of neuropeptide Y (NPY; 0.235-2.35 nmol) into the posterior hypothalamic nucleus was found to evoke a concentration-dependent increase in mean arterial pressure (MAP) of Urethane-anesthetized rats. Concentration-dependent pressor responses were also elicited by unilateral administration of histamine (0.543-17.9 nmol) into the posterior hypothalamic nucleus. Administration of 30 nmol of the histamine H1-receptor antagonist, chlorpheniramine, but not 43.5 nmol of the histamine H2-receptor antagonist, cimetidine, into the posterior hypothalamic nucleus 10 min before 5.43 nmol histamine administration, significantly attenuated the histamine-induced pressor response. These concentrations of chlorpheniramine or cimetidine did not affect the increase in MAP, which could be evoked by the administration of 5.48 nmol of the cholinergic muscarinic agonist carbachol into the posterior hypothalamic nucleus. The carbachol-induced increase in MAP was, however, completely blocked by administration of 12 nmol of the cholinergic muscarinic antagonist atropine into the posterior hypothalamic nucleus 10 min before carbachol administration. This concentration of atropine did not affect the histamine-induced pressor response. Administration of atropine or chlorpheniramine into the posterior hypothalamic nucleus 10 min before 2.35 nmol NPY significantly attenuated the pressor response evoked by NPY. Cimetidine, on the other hand, was unable to significantly affect the increase in MAP evoked by NPY. These results demonstrate that NPY administered into the posterior hypothalamic nucleus can elicit a pressor response, and that this pressor response might involve local histaminergic and cholinergic neuronal pathways.

Animals↗

Peptides in rat brain immunoreactive for the amino terminus of cholecystokinin 33: distribution and chromatography.

Antisera directed against the amino-terminus of porcine CCK 33 detects related immunoreactivity in rat brain extracts, the distribution of which follows that of CCK 8. Sephadex chromatography indicates that several immunoreactive peptides are present with a molecular weight range of 2600-3500. These peptides are likely to be CCK 39 or CCK 33 and the amino terminal segments of CCK 39/33 without the CCK 8 sequence. The presence of CCK 39/33 and its amino-terminal fragments without CCK 22 and its amino-terminal fragments confirms the absence of CCK 22 in the rat brain. This cleavage at CCK 22 is one of the major differences between the processing of CCK in rat brain and gut and may reflect differences in their physiological roles.

Animals↗

Lithium preincubation stimulates the potassium-induced release of cholecystokinin from slices of cerebral cortex and caudate-putamen incubated in vitro.

Potassium-evoked cholecystokinin (CCK) release from slices of caudate-putamen and cerebral cortex, but not hippocampus incubated in vitro was increased by 152-175% by preincubation for 40 min with 10 mM lithium. These results and previous studies suggest that although different physiological agents regulate CCK release in these brain regions, these agents may share a common intracellular mediator which may be a product of inositol phospholipid turnover.

Animals↗

Hypothalamic neurotoxins alter the content of immunoreactive cholecystokinin in pituitary.

Monosodium glutamate and bipiperidyl mustard both produce mediobasal hypothalamic lesions and have been reported to alter the subsequent feeding behavior and/or insulin levels of treated animals. In our previous studies bipiperidyl mustard alone had no effects on insulin levels or feeding, but in combination with glutamate produced hyperphagic obesity. Administration of exogenous cholecystokinin octapeptide also has been shown to affect feeding behavior and plasma insulin. In order to determine if endogenous cholecystokinin played a role in the effects of glutamate or bipiperidyl mustard, concentrations of cholecystokinin in the pituitary glands of lesioned rats were measured. Bipiperidyl mustard alone increased cholecystokinin content while combined lesioning with glutamate prevented the increase. The potential role of cholecystokinin-containing elements of the hypothalamus and pituitary in modulation of feeding is discussed.

Animals↗

The regulation of cholecystokinin release from rat caudatoputamen in vitro.

Cholecystokinin (CCK) is one of the most abundant neuropeptides in the rat caudatoputamen (cp). CCK perikarya innervating cp are thought to originate in neurons in the claustrum/piriform cortex area of the amygdala. Previous studies on the release of CCK from cp have focused on the influence of dopamine agonists. The present study has examined the influence of other neuroactive substances on the release of CCK. The release of CCK from rat cp slices in vitro stimulated by potassium was quantitated with a specific CCK radioimmunoassay. This potassium-stimulated release of CCK was Ca2+-dependent. Maximal stimulation of CCK release was observed at 55 mM potassium. Several lines of evidence indicate that the release of CCK from cp is inhibited by some other substance (or substances) released by a Ca2+-dependent mechanism from cp along with CCK. Release media from cerebral cortex or cp (called 'conditioned media' or CM) inhibits the release of CCK from fresh slices of cp but not from cerebral cortex. The release of dopamine from cp is unaffected by CM from cortex or cp. The identity of the substance in CM which inhibits CCK release from cp is still under investigation, though it appears not to be CCK, dopamine, acetylcholine, somatostatin, leucine enkephalin or gamma-aminobutyric acid.

Animals↗

Effect of stimulation of endogenous glucagon secretion by amino acid administration on canine hepatic bile flow.

Exogenous glucagon administration is associated with stimulation of hepatic bile flow. The physiologic role that glucagon plays in the control of hepatic bile flow remains indeterminant. The purpose of this study was to evaluate amino acid administration, a stimulus of endogenous glucagon release, on canine hepatic bile flow. The experiments were performed utilizing cholecystectomized dogs with chronic biliary fistulas. The enterohepatic circulation of bile salts was artificially maintained by intravenous bile salt administration. Intravenous L-arginine stimulated endogenous glucagon release and hepatic bile secretion. Intravenous amino acid administration produced significant increases in hepatic bile flow and plasma glucagon and was significantly more potent than intravenous arginine. Intravenous amino acid administration produced small but significant increases in serum insulin but did not significantly change plasma concentrations of cholecystokinin. The results of this study suggest that endogenous glucagon secretion produces a choleresis and supports a role for glucagon in the physiologic control of canine hepatic bile flow.

Amino Acids↗

Effects of somatostatin on acute canine experimental pancreatitis.

Somatostatin is an inhibitory hormone that decreases the secretion and end organ response of cholecystokinin (CCK). Inhibition of hormonal stimulation of pancreatic exocrine secretion by somatostatin may improve the course of acute pancreatitis. Anesthetized dogs underwent cholecystectomy and cannulation of the pancreatic duct, thoracic duct, and portal vein. Twenty experiments were performed in random order with 5 dogs in each group. Hourly measurements of lymph flow and portal and thoracic duct amylase were made. Portal blood insulin, glucagon, and CCK concentrations were determined by radioimmunoassay on samples obtained at the beginning and end of the experiments. Pancreatitis was induced by injecting, under constant pressure, 10 ml bile into the pancreatic duct during 1 min. Somatostatin was administered intravenously (20 micrograms/kg/hr). After 5 h, the dogs were killed, pancreas glands removed and weighed and tissue samples obtained for histologic evaluation. There was a significant increase in lymph amylase output and portal venous amylase and CCK concentrations in the dogs with pancreatitis compared to the control dogs. In dogs with pancreatitis, lymphatic amylase secretion and portal CCK concentrations were significantly decreased by somatostatin. Somatostatin did not significantly alter portal amylase concentrations, pancreas gland weights or histologic inflammation when compared to values from dogs with pancreatitis not treated with somatostatin.

Acute Disease↗

Exogenous cholecystokinin (CCK) reduces neonatal rat brain opioid receptor density and CCK levels.

Newborn rats were given saline or cholecystokinin8 (CCK8) (5 micrograms/kg, twice daily) i.p. for 3 weeks. On day 21, effects on brain development were assessed. CCK-like immunoreactivity was measured in 7 brain regions; a small (12-18%) but significant decrease in endogenous levels of this peptide was detected in cerebral cortex, medulla and pons of the CCK-treated rats. Morphometric measurements revealed a slight reduction in thickness of most cerebral cortical sections within the CCK-treated group. The area of a midsagittal section of the cerebellum was unchanged except for the Purkinje/granule cell layer, which was smaller in CCK-treated animals. Levels of mu-, delta- and kappa-opioid receptors were estimated by homologous displacement binding assays using selective radioligands. The CCK treatment resulted in a significant decrease in levels of mu- (11%) and delta- (13%)-sites in the cerebral cortex. Neither binding affinities nor kappa-receptor densities were altered. Other animals received the same treatment regimens for 21 days and were maintained for an additional 29 days without treatment; these rats had reductions only in cortical mu-sites (15%). Chronic intraventricular administration of CCK (0.1 microgram/h) to adult rats did not elicit a similar down-regulation of cortical mu or delta receptors, suggesting that the effects observed in neonates reflected developmental processes.

Animals↗

Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat.

The effect of neuropeptide Y (NPY) on periarterial nerve stimulation-induced release of norepinephrine (NE) and increase in perfusion pressure in the perfused mesenteric arterial bed of the rat was examined. Perfusate effluents were continuously collected and assayed for endogenous NE by high-pressure liquid chromatography (HPLC) coupled to electrochemical detection. Perfusion pressure was continuously monitored by means of a pressure transducer. Periarterial nerve stimulation (8 or 16 Hz, 60 V, 2-ms duration for 30 s) resulted in a readily detectable increase in NE release and perfusion pressure that was attenuated by the prior administration of tetrodotoxin (TTX) (10(-5) M) or guanethidine (5 X 10(-5) M). NPY exerted both prejunctional and postjunctional effects on noradrenergic neurotransmission in this preparation. The peptide produced a concentration-dependent reduction in the release of NE over a concentration range of 10(-10) - 10(-7) M. A similar inhibition effect occurred at 8, 10, and 16 Hz. In contrast, low concentrations (10(-10) and 10(-9) M) decreased the effect of nerve stimulation on perfusion pressure, whereas higher concentrations (10(-7) M) produced a marked potentiation. The alpha 2-adrenoceptor antagonist, yohimbine, did not alter the inhibitory effect of NPY on evoked NE release or the effect on perfusion pressure. Prazosin similarly did not alter the inhibitory effect of NPY on NE release but prevented the increase in perfusion pressure. We conclude that NPY modulates noradrenergic neurotransmission in the mesenteric arterial bed by decreasing the evoked release of NE and producing a concentration-dependent biphasic response on vascular smooth muscle.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor.

The effect of specific D-2 dopamine (DA) receptor agonists and antagonists on potassium (55 mM)-evoked release of cholecystokinin-like immunoreactivity (CCK-LI) was studied in tissue slices of the rat posterior nucleus accumbens (NAc). Incubating the tissue slices in 100 nM or 1 microM of LY-141865, a specific D-2 DA receptor agonist, reduced the release of CCK-LI as indicated by a significant decrease in the S2/S1 ratio. Addition of 10 microM of (-)-sulpiride, a specific D-2 DA receptor antagonist, blocked the inhibitory effect of 100 nM of LY-141865 on the release of CCK-LI. In contrast, 10 microM of the specific D-1 DA receptor antagonist SCH 23390 was unable to attenuate the decrease in release of CCK-LI caused by 100 nM of LY-141865. Furthermore, the active isomer of LY-141865, LY-171555 at 0.1 to 50 nM, also decreased the release of CCK-LI from the tissue slices, while the inactive isomer, LY-181990 at 1 nM, did not affect CCK-LI release. The inhibitory effect of LY-171555 on the release of CCK-LI was lost when its concentration was increased to 100 nM, thus revealing a biphasic effect of D-2 DA receptor stimulation on the release of CCK-LI. These results demonstrate that stimulation of D-2 DA receptor can modulate the release of CCK from in vitro slices of the rat posterior NAc.

Animals↗

Increase in hypothalamic cholecystokinin following acute and chronic morphine.

Recent evidence supports an antagonistic interaction between cholecystokinin (CCK) and opiate peptides. The present study determined the effects of various levels of morphine treatment on hypothalamic levels of CCK as determined by radioimmunoassay. Acute treatment with morphine sulfate (10 mg/kg) or implantation of one morphine pellet (75 mg free base) increased levels of CCK in whole hypothalamus. Increased exposure to morphine by either chronic injections or implantation of two pellets did not result in a further change in whole hypothalamic CCK levels. In samples dissected into hypothalamic subregions, the effect of morphine on CCK levels was localized to medial but not lateral or posterior regions. These experiments extend earlier in vitro findings and suggest that some of the physiological and behavioral effects of opiate peptides may result from modulation of endogenous CCK.

Animals↗

Vasoactive intestinal polypeptide (VIP) inhibits potassium-induced release of cholecystokinin (CCK) from rat caudato-putamen but not from cerebral cortex.

CCK release elicited by 40 mM potassium from slices of rat caudato-putamen (cp) was inhibited by VIP. The effect of VIP was maximal at 10(-7) M. VIP does not inhibit CCK release from cerebral cortex at either 10(-7) or 10(-6) M. VIP is known to elevate levels of cAMP in rat brain. VIP inhibition of CCK release appears to be independent of activation of adenylate cyclase because treatment of cp slices with forskolin (2 X 10(-6) to 10(-4) M) does not mimic the inhibitory action of VIP.

Animals↗

Motilin-related immunoreactivity in mammalian adenohypophysis.

Motilin, a gut peptide recently demonstrated in the mammalian brain and anterior pituitary, was localized immunocytochemically in rat, guinea pig, and human anterior pituitary glands with two antisera to synthetic porcine motilin. Adjacent sections of normal glands were immunostained for motilin, growth hormone, and prolactin reactivity. Motilin reactivity was consistently seen in somatotrophic regions of the mammalian glands and in many instances was colocalized in individual somatotrophs traced in adjacent sections stained for growth hormone. There was no motilin activity discerned in prolactin-secreting regions of the gland. These studies reinforce the close relationship of motilin or a motilin-like peptide with growth hormone in normal somatotrophs. Further anatomical and in vitro studies with tumor material will be useful in elucidating the physiological relationship of motilin to growth hormone.

Animals↗

Cholecystokinin (CCK) gene-related peptides: distribution and characterization of immunoreactive pro-CCK and an amino-terminal pro-CCK fragment in rat brain.

An antiserum specific for the amino terminus of pro-CCK detects 3 major peptides in rat brain with molecular weights of 13,000, 8000 and 2700 daltons. These peptides are abundant both in CCK terminal-field regions and regions rich in CCK perikarya. The two high molecular weight peptides probably represent CCK precursor molecules. The smaller peptide is probably the amino-terminal fragment of pro-CCK and may be stored and released along with CCK-8, and have a potential role in synaptic transmission.

Animals↗

The distribution of chromatographic characterization of an amino-terminal fragment of cholecystokinin (CCK) 58 in rat brain.

Utilizing a specific antiserum against CCK 58, a single immunoreactive peptide of about 1750 daltons was detected in rat brain extracts. It is distributed in all rat brain regions containing CCK 8, though it is most abundant in areas where CCK terminals predominate (septum, striatum and olfactory tubercle/nucleus accumbens). Based on its molecular weight, it is probably the amino terminal portion of CCK 58 left when CCK 39 is cleaved, and it may represent an intermediate in the processing of pre-pro-CCK. The presence of this peptide in CCK terminal areas implies that the proteolytic cleavage of CCK 58 occurs late in the processing, possibly in synaptic vesicles. It is also possible that this peptide can be released along with CCK 8 and exert an influence on synaptic transmission.

Animals↗

The distribution of motilin-like peptides in rhesus monkey brain as determined by radioimmunoassay.

The distribution of motilin-like immunoreactivity (MLI) was determined by radioimmunoassay in the major regions of rhesus monkey brain. In agreement with previous studies, motilin concentration was higher in pituitary and pineal than brain. MLI was widely distributed in rhesus monkey brain and was particularly high in claustrum, inferior colliculus, and cerebellar floculus. Sephadex G50 chromatography of monkey cerebellar and cerebral cortical extracts revealed multiple forms of MLI. The presence of MLI in rhesus monkey brain confirms previous reports of localization of motilin-like peptides by immunocytochemistry in the human cerebellum and is suggestive of a possible role for MLI in the functioning of the human brain.

Animals↗

The subcellular distribution of peptides immunoreactive for the carboxyl-terminal extension of cholecystokinin in rat brain.

An antiserum raised against a synthetic peptide (D-10-Y) comprising the carboxyl-terminal extension of cholecystokinin (CCK) detects several immunoreactive peptides, which were found to be widely distributed in rat brain (1). This article reports the subcellular distribution of these D-10-Y-like immunoreactive peptides in whole rat brain. Primary subcellular fractionation yielded a mitochondrial (P2) and microsomal (P3) fraction, both of which were enriched in D-10-Y and CCK 8 peptide immunoreactivity. Further fractionation of P2 yielded a purified synaptosome fraction (P4) which was further enriched in D-10-Y and CCK 8-like peptides. Whole rat brain contains two major molecular forms of D-10-Y-like immunoreactivity, one similar in size to CCK 33 (peak 1) and one slightly larger than CCK 8 (peak 2). In the P2 and P3 fractions, most of the D-10-Y-like immunoreactivity was similar in size to peak 2. It is likely that this D-10-Y-like immunoreactive peptide is an intermediate in the processing of CCK 8, and its enrichment in nerve endings is consistent with the final cleavage and amidation reactions taking place in the nerve terminals.

Animals↗

The subcellular distribution of peptides immunoreactive for the amino-terminal of pro-cholecystokinin in rat brain.

Antiserum 1942 raised against the synthetic peptide V-9-M is specific for the amino-terminus of pro-cholecystokinin (pro-CCK). It detects three major peptides in whole rat brain extracts with molecular weights of about 13 000 (peak 1), 8000 (peak 2) and 2700 (peak 3), of which the major one is peak 3. Rat brain was found to contain large quantities of these V-9-M-like peptides. Subcellular fractionation of whole rat brain was performed to determine what cellular component was enriched in these peptides. The molecular weight of the V-9-M-like and CCK-8-like peptides enriched in various subcellular fractions has been determined by Sephadex G-50 chromatography. Primary subcellular fractionation experiments indicated a significant enrichment of V-9-M-like peptides in the mitochondrial pellet (P2), a lesser amount in the microsomal pellet (P3), and a slight enrichment in the soluble fraction (S3). Further purification of the P2 fraction demonstrated an increase of V-9-M-like immunoreactivity in purified synaptosomes. With the exception of the enrichment in the soluble fraction, V-9-M-like peptides follow a similar distribution to that of CCK-8-like peptides. Sephadex chromatography of P2 and P3 fractions indicates that the major form of V-9-M present is the peak 3 (2700) form. This V-9-M-like peptide may represent an intermediate in the processing of CCK, and its presence in synaptosomes may indicate that the proteolytic cleavage of pro-CCK into CCK 58 and peak 3 takes place in synaptic vesicles.

Amino Acid Sequence↗